| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P2093 | author name string | Lynne V McFarland | |
| P2860 | cites work | Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. | Q51680807 |
| Epidemiology, risk factors and treatments for antibiotic-associated diarrhea | Q52533461 | ||
| A Randomized Formula Controlled Trial of Bifidobacterium lactis and Streptococcus thermophilus for Prevention of Antibiotic-Associated Diarrhea in Infants | Q58227623 | ||
| Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis | Q24529831 | ||
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Assessment of a new synbiotic preparation in healthy volunteers: survival, persistence of probiotic strains and its effect on the indigenous flora | Q24791618 | ||
| Finding qualitative research: an evaluation of search strategies | Q24803628 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting | Q27861077 | ||
| Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG | Q28234977 | ||
| Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial | Q28237525 | ||
| A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease | Q28254686 | ||
| Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children | Q29028534 | ||
| Systematic reviews in health care: Assessing the quality of controlled clinical trials | Q29618659 | ||
| Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study. | Q31927463 | ||
| Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea | Q33222511 | ||
| Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study | Q33426019 | ||
| Possible role of catheters in Saccharomyces boulardii fungemia | Q33856125 | ||
| Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study | Q33878836 | ||
| Current methods of the US Preventive Services Task Force: a review of the process | Q33942708 | ||
| Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. | Q33960898 | ||
| Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. QUOROM Group | Q34089161 | ||
| Saccharomyces cerevisiae fungemia: an emerging infectious disease | Q34557580 | ||
| Rifampicin resistance in tuberculosis outbreak, London, England | Q36009343 | ||
| Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials? | Q36108490 | ||
| Meta-analysis: Principles and procedures | Q36247440 | ||
| Empirical assessment of effect of publication bias on meta-analyses. | Q38630464 | ||
| Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice | Q39519683 | ||
| Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone | Q40741794 | ||
| Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial | Q44222933 | ||
| Clostridium difficile infections related to antibiotic use and infection control facilities in two university hospitals | Q44509461 | ||
| Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting | Q44561271 | ||
| Health Care Costs and Mortality Associated with Nosocomial Diarrhea Due to Clostridium difficile | Q45164970 | ||
| Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial | Q45166053 | ||
| Prevalence and characteristics of bacteria and host factors in an outbreak situation of antibiotic-associated diarrhoea | Q45240121 | ||
| Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea | Q45264302 | ||
| Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study | Q46478436 | ||
| The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients | Q50891759 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibiotic | Q12187 |
| probiotics | Q1816730 | ||
| diarrhea | Q40878 | ||
| Clostridium difficile | Q310543 | ||
| meta-analysis | Q815382 | ||
| P304 | page(s) | 812-822 | |
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | The American Journal of Gastroenterology | Q7713501 |
| P1476 | title | Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease | |
| P478 | volume | 101 |
| Q63230054 | 2019 update of the WSES guidelines for management of () infection in surgical patients |
| Q41001486 | A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). |
| Q34378800 | A Double-Blind, Randomized, Active Drug Comparative, Parallel-Group, Multi-Center Clinical Study to Evaluate the Safety and Efficacy of Probiotics (Bacillus licheniformis, Zhengchangsheng® capsule) in Patients with Diarrhea |
| Q43871970 | A Lactobacillus casei Shirota probiotic drink reduces antibiotic-associated diarrhoea in patients with spinal cord injuries: a randomised controlled trial. |
| Q31057363 | A Meta-Analysis of Probiotic Efficacy for Gastrointestinal Diseases |
| Q61815572 | A Review on Gut Remediation of Selected Environmental Contaminants: Possible Roles of Probiotics and Gut Microbiota |
| Q36179468 | A gastroenterologist's guide to probiotics |
| Q34257705 | A multicentre randomised controlled trial evaluating lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea in older people admitted to hospital: the PLACIDE study protocol. |
| Q58798841 | A practical guide for probiotics applied to the case of antibiotic-associated diarrhea in The Netherlands |
| Q41992918 | A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO). |
| Q37574992 | Advances in Gut Microbiome Research, Opening New Strategies to Cope with a Western Lifestyle |
| Q35678151 | Aging of the human metaorganism: the microbial counterpart |
| Q35105259 | Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome. |
| Q53685610 | Anti-biofilm Properties of the Fecal Probiotic Lactobacilli Against Vibrio spp. |
| Q37712802 | Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents |
| Q33786181 | Antibiotic precautions in athletes |
| Q34386251 | Antibiotic resistance-the need for global solutions |
| Q37277087 | Antibiotic-associated diarrhea: epidemiology, trends and treatment |
| Q40690828 | Antibiotic-associated diarrhoea in emergency department observation unit patients |
| Q41393552 | Bacillus amyloliquefaciens as prophylactic treatment for Clostridium difficile-associated disease in a mouse model |
| Q36463014 | Bacterial probiotics as an aid in the control of Clostridium difficile disease in neonatal pigs |
| Q40118114 | Beneficial Effect of Bifidobacterium longum ATCC 15707 on Survival Rate of Clostridium difficile Infection in Mice |
| Q37976693 | Beneficial effects of probiotic and food borne yeasts on human health |
| Q35225117 | Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease |
| Q38700599 | Biogeography and ecological diversity patterns of rare and abundant bacteria in oil-contaminated soils. |
| Q38225464 | Bugs or drugs: are probiotics safe for use in the critically ill? |
| Q64067716 | CNCM I-745 Modulates the Fecal Bile Acids Metabolism During Antimicrobial Therapy in Healthy Volunteers |
| Q34981520 | Can probiotic yogurt prevent diarrhoea in children on antibiotics? A double-blind, randomised, placebo-controlled study |
| Q44538529 | Changes in bacterial glycolipids as an index of intestinal lactobacilli and epithelial glycolipids in the digestive tracts of mice after administration of penicillin and streptomycin |
| Q28828166 | Chemical characterization and immunomodulatory properties of polysaccharides isolated from probiotic Lactobacillus casei LOCK 0919 |
| Q41545688 | Clinical Characteristics of Symptomatic Clostridium difficile Infection in Children: Conditions as Infection Risks and Whether Probiotics Is Effective |
| Q26769032 | Clinical Uses of Probiotics |
| Q91948457 | Clinical effect of probiotics in prevention or treatment of gastrointestinal disease in dogs: A systematic review |
| Q36903688 | Clinical management of Clostridium difficile-associated disease |
| Q33463810 | Clinical safety and efficacy of probiotic administration following burn injury |
| Q37633859 | Clinical update for the diagnosis and treatment of Clostridium difficile infection |
| Q46324386 | Close association between intestinal microbiota and irritable bowel syndrome |
| Q37977204 | Clostridium Difficile Infection in Older Adults: A Review and Update on Its Management |
| Q41172353 | Clostridium butyricum combined with Bifidobacterium infantis probiotic mixture restores fecal microbiota and attenuates systemic inflammation in mice with antibiotic-associated diarrhea. |
| Q38090899 | Clostridium difficile Infection and Inflammatory Bowel Disease |
| Q35208564 | Clostridium difficile Infection and Inflammatory Bowel Disease: A Review. |
| Q37427674 | Clostridium difficile colitis |
| Q30239988 | Clostridium difficile infection: Updates in management |
| Q26750157 | Clostridium difficile infection: a review of current and emerging therapies |
| Q44549564 | Clostridium difficile infection: a surgical disease in evolution |
| Q37814046 | Clostridium difficile infection: epidemiology, risk factors and management |
| Q29615330 | Clostridium difficile infection: new developments in epidemiology and pathogenesis |
| Q92835483 | Clostridium difficile infection: review |
| Q41557906 | Clostridium difficile infection: risk factors, diagnosis and management |
| Q38028945 | Clostridium difficile outbreaks: prevention and treatment strategies |
| Q36757577 | Clostridium difficile-associated disease: changing epidemiology and implications for management |
| Q26827693 | Clostridium difficile: epidemiology, diagnostic and therapeutic possibilities-a systematic review |
| Q34260389 | Clostridium difficileColitis: A Review |
| Q38105355 | Clostridium difficileinfection in children: a comprehensive review |
| Q34499198 | Commercially available probiotic drinks containing Lactobacillus casei DN-114001 reduce antibiotic-associated diarrhea |
| Q53188361 | Competence and sporulation factor derived from Bacillus subtilis improves epithelial cell injury in intestinal inflammation via immunomodulation and cytoprotection |
| Q41864813 | Complete Genome Sequence of Lactobacillus casei LC5, a Potential Probiotics for Atopic Dermatitis |
| Q35412870 | Compositional dynamics of the human intestinal microbiota with aging: implications for health. |
| Q37111213 | Conceptualizing human microbiota: from multicelled organ to ecological community |
| Q92538107 | Consortium of Probiotics Attenuates Colonization of Clostridioides difficile |
| Q37871423 | Current Trends in Critical Care Nutrition |
| Q38217016 | Deciphering meta-analytic results: a mini-review of probiotics for the prevention of paediatric antibiotic-associated diarrhoea and Clostridium difficile infections |
| Q34736772 | Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea |
| Q38002427 | Detecting and Treating Clostridium Difficile Infections in Patients with Inflammatory Bowel Disease |
| Q37995460 | Detection, Treatment, and Prevention of Clostridium difficile Infection |
| Q37774413 | Diagnosis, management, and prevention of Clostridium difficile infection in long-term care facilities: a review |
| Q42592374 | Diarrhoea associated with antibiotic use. |
| Q36191041 | Disease Prevention and Health Promotion: How Integrative Medicine Fits |
| Q41970910 | Effect of Lactobacillus acidophilus & epidermal growth factor on experimentally induced Clostridium difficile infection |
| Q85565648 | Effect of a single dose of Saccharomyces cerevisiae var. boulardii on the occurrence of porcine neonatal diarrhoea |
| Q34208812 | Effect of oral administration of metronidazole or prednisolone on fecal microbiota in dogs. |
| Q34369059 | Effect of probiotic Lactobacillus (Lacidofil® cap) for the prevention of antibiotic-associated diarrhea: a prospective, randomized, double-blind, multicenter study |
| Q37694119 | Effect of probiotic administration in the therapy of pediatric thermal burn |
| Q38826535 | Effect of probiotics on body weight and body-mass index: a systematic review and meta-analysis of randomized, controlled trials |
| Q40044003 | Effects of Probiotics, Prebiotics, and Synbiotics on Human Health |
| Q57226635 | Effects of antibiotic therapy on the gastrointestinal microbiota and the influence ofLactobacillus casei |
| Q57792020 | Effects of chlortetracycline alone or in combination with direct fed microbials on nursery pig growth performance and antimicrobial resistance of fecal Escherichia coli |
| Q33877152 | Effects of consumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 on common respiratory and gastrointestinal infections in shift workers in a randomized controlled trial |
| Q91725055 | Effects of probiotic administration on IGA and IL-6 level in severe burn patients: a randomized trial |
| Q34209418 | Effects of probiotics and antibiotics on the intestinal homeostasis in a computer controlled model of the large intestine |
| Q37994188 | Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders |
| Q35755346 | Efficacy of BIO K+ CL1285 in the reduction of antibiotic-associated diarrhea - a placebo controlled double-blind randomized, multi-center study |
| Q38661942 | Efficacy of probiotic use in acute rotavirus diarrhea in children: A systematic review and meta-analysis |
| Q89731185 | Efficacy of probiotics on cognition, and biomarkers of inflammation and oxidative stress in adults with Alzheimer's disease or mild cognitive impairment - a meta-analysis of randomized controlled trials |
| Q35205214 | Emerging science of the human microbiome |
| Q37721203 | Enhanced Probiotic Potential of Lactobacillus reuteri When Delivered as a Biofilm on Dextranomer Microspheres That Contain Beneficial Cargo |
| Q37957247 | Enteropathogenic Bacteria in Dogs and Cats: Diagnosis, Epidemiology, Treatment, and Control |
| Q35733944 | Factors influencing the development of antibiotic associated diarrhea in ED patients discharged home: risk of administering IV antibiotics |
| Q34611463 | Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series |
| Q40291508 | Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients |
| Q38108088 | Feeding the immune system |
| Q37588248 | Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance |
| Q34286137 | Fighting Fire with Fire: Is it Time to Use Probiotics to Manage Pathogenic Bacterial Diseases? |
| Q85067107 | Food & health forum meeting: evidence-based nutrition |
| Q37963031 | Food Formats for Effective Delivery of Probiotics |
| Q37514810 | Functional foods: what are the benefits? |
| Q38794312 | Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. |
| Q37682514 | Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics |
| Q34329633 | Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections |
| Q57169033 | Gut microbes as future therapeutics in treating inflammatory and infectious diseases: Lessons from recent findings |
| Q27024802 | Health benefits of probiotics: a review |
| Q50002686 | How Common-and How Serious- Is Clostridium difficile Colitis After Geriatric Hip Fracture? Findings from the NSQIP Dataset. |
| Q38006996 | Immunization strategies for Clostridium difficile infections |
| Q42613120 | Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital |
| Q92741954 | Impact of endurance exercise and probiotic supplementation on the intestinal microbiota: a cross-over pilot study |
| Q35952315 | Impact of probiotic supplements on microbiome diversity following antibiotic treatment of mice |
| Q37798821 | Impact ofClostridium difficileon inflammatory bowel disease |
| Q43051294 | Important drug-nutrient interactions |
| Q92510137 | Inconsistency in Diarrhea Measurements when Assessing Intervention Impact in a Non-Blinded Cluster-Randomized Controlled Trial |
| Q37969593 | Indications for the Use of Probiotics in Gastrointestinal Diseases |
| Q45999250 | Infections caused by Clostridium difficile. Addendum |
| Q38234198 | Infectious diarrhea: an overview |
| Q28066899 | Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system |
| Q47102862 | Inhibition effect of Bifidobacterium longum, Lactobacillus acidophilus, Streptococcus thermophilus and Enterococcus faecalis and their related products on human colonic smooth muscle in vitro. |
| Q37666863 | Innate immune dysfunction in acute and chronic liver disease |
| Q39369353 | Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. |
| Q21198789 | Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells |
| Q37576841 | Lactobacillus reuteri DSM 17938 in the prevention of antibiotic-associated diarrhoea in children: protocol of a randomised controlled trial |
| Q33890323 | Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells |
| Q64118375 | Mechanistic Insights Into Probiotic Properties of Lactic Acid Bacteria Associated With Ethnic Fermented Dairy Products |
| Q37156630 | Meta-analysis of probiotics for the treatment of irritable bowel syndrome |
| Q47858003 | Meta‐analysis: probiotics in antibiotic‐associated diarrhoea |
| Q39281119 | Microbiota and probiotics: effects on human health |
| Q92921981 | Microbiota-Immune Interaction in the Pathogenesis of Gut-Derived Infection |
| Q34602195 | New antimicrobial agents for patients with Clostridium difficile infections |
| Q35862915 | Novel approaches to treating Clostridium difficile-associated colitis. |
| Q39868711 | Novel perspectives in probiotic treatment: the efficacy and unveiled mechanisms of the physiological functions |
| Q38585203 | Nutraceuticals for blood pressure control. |
| Q39708827 | Orally Administered Salacia reticulata Extract Reduces H1N1 Influenza Clinical Symptoms in Murine Lung Tissues Putatively Due to Enhanced Natural Killer Cell Activity |
| Q35701455 | Overview of the gastrointestinal microbiota |
| Q36696682 | PURLs: prescribing an antibiotic? Pair it with probiotics |
| Q26771942 | Part 2: Treatments for Chronic Gastrointestinal Disease and Gut Dysbiosis |
| Q36674768 | Past, present, and future therapies for Clostridium difficile-associated disease |
| Q92004174 | Patient satisfaction with nursing care in Ethiopia: a systematic review and meta-analysis |
| Q36271715 | Pharmacologic Agents for Chronic Diarrhea |
| Q53585398 | Polyphosphate, an active molecule derived from probiotic Lactobacillus brevis, improves the fibrosis in murine colitis |
| Q37962875 | Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults |
| Q64227893 | Precision medicine: retrospective chart review and data analysis of 200 patients on dapsone combination therapy for chronic Lyme disease/post-treatment Lyme disease syndrome: part 1 |
| Q39056083 | Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice. |
| Q38172838 | Prevalence of systemic inflammation and micronutrient imbalance in patients with complex abdominal hernias. |
| Q37197599 | Prevention and treatment of urinary tract infection with probiotics: Review and research perspective |
| Q38448285 | Prevention of Clostridium difficile Infection With Probiotics |
| Q37770405 | Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence |
| Q37177819 | Prevention of hospital-acquired infections: review of non-pharmacological interventions |
| Q40579622 | Probiotic Saccharomyces boulardii CNCM I-745 prevents outbreak-associated Clostridium difficile-associated cecal inflammation in hamsters |
| Q92442433 | Probiotic Supplementation in a Clostridium difficile-Infected Gastrointestinal Model Is Associated with Restoring Metabolic Function of Microbiota |
| Q34723329 | Probiotic Yeast Inhibits VEGFR Signaling and Angiogenesis in Intestinal Inflammation |
| Q36953712 | Probiotic agents in the treatment of irritable bowel syndrome |
| Q38811781 | Probiotic approach to prevent antibiotic resistance. |
| Q42876116 | Probiotic encapsulation technology: from microencapsulation to release into the gut. |
| Q84837086 | Probiotic lactobacilli and bifidobacteria in a fermented milk product with added fruit preparation reduce antibiotic associated diarrhea and Helicobacter pylori activity |
| Q39265808 | Probiotic treatment for the prevention of antibiotic-associated diarrhoea in geriatric patients: a multicentre randomised controlled pilot study |
| Q53765712 | Probiotics - is there evidence for use against antibiotic induced diarrhea, CDAD and travellers diarrhea? |
| Q38821454 | Probiotics Reduce the Risk of Antibiotic-Associated Diarrhea in Adults (18-64 Years) but Not the Elderly (>65 Years): A Meta-Analysis. |
| Q38644810 | Probiotics and Fecal Microbiota Transplant for Primary and Secondary Prevention of Clostridium difficile Infection |
| Q34162963 | Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science |
| Q38125810 | Probiotics and clinical effects: is the number what counts? |
| Q37460752 | Probiotics and gastrointestinal disease: successes, problems and future prospects |
| Q38081229 | Probiotics and prebiotics in pediatric diarrheal disorders |
| Q36567134 | Probiotics and the gut microbiota in intestinal health and disease |
| Q36862309 | Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii |
| Q38303539 | Probiotics for antibiotic-associated diarrhea: do we have a verdict? |
| Q37423648 | Probiotics for preventive health |
| Q36683562 | Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review |
| Q27015021 | Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis |
| Q24186991 | Probiotics for the prevention of pediatric antibiotic-associated diarrhea |
| Q24235039 | Probiotics for the prevention of pediatric antibiotic-associated diarrhea |
| Q24245196 | Probiotics for the prevention of pediatric antibiotic-associated diarrhea |
| Q91644124 | Probiotics for the prevention of pediatric antibiotic-associated diarrhea |
| Q34223543 | Probiotics in Clostridium difficile Infection |
| Q82416873 | Probiotics in Gastrointestinal Disorders |
| Q86153118 | Probiotics in gastroenterology -- from a different angle |
| Q36816072 | Probiotics in paediatric gastrointestinal diseases. |
| Q33438518 | Probiotics in the management of colonic disorders |
| Q37892873 | Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection |
| Q35056944 | Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study |
| Q37401594 | Probiotics, critical illness, and methodologic bias |
| Q28087443 | Probiotics, prebiotics and synbiotics- a review |
| Q37054669 | Probiotics--industry myth or a practical reality? |
| Q33445442 | Probiotics. |
| Q84390503 | Probiotics: beneficial factors of the defence system |
| Q57121182 | Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed Saccharomyces boulardii |
| Q51753980 | Protective effect of a mixture of kefir-isolated lactic acid bacteria and yeasts in a hamster model of Clostridium difficile infection |
| Q86624181 | Pseudomembranous Colitis in Cystic Fibrosis |
| Q35966327 | Quantitative real time PCR detection of Clostridium difficile growth inhibition by probiotic organisms |
| Q37312055 | Randomised clinical trial: symptoms of the irritable bowel syndrome are improved by a psycho‐education group intervention |
| Q34322219 | Randomized pilot trial of a synbiotic dietary supplement in chronic HIV-1 infection |
| Q52657241 | Recent Progress for the Effective Prevention and Treatment of Recurrent Clostridium difficile Infection |
| Q42871284 | Recent advances in Saccharomyces boulardii research |
| Q58591772 | Recurrent Infection: Risk Factors, Treatment, and Prevention |
| Q36978854 | Refractory Clostridium difficile-associated diarrhea. |
| Q35804961 | Regulatory Oversight and Safety of Probiotic Use |
| Q37586528 | Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii |
| Q34094620 | Role of Lactobacillus in the prevention of antibiotic-associated diarrhea: a meta-analysis |
| Q44147671 | Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial |
| Q35863469 | Saccharomyces boulardii fungemia caused by treatment with a probioticum |
| Q36670919 | Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial |
| Q40099400 | Saccharomyces cerevisiae var. boulardii fungemia following probiotic treatment. |
| Q35725903 | Safety assessment ofBifidobacterium longumJDM301 based on complete genome sequences |
| Q47151847 | Scientific Opinion on the substantiation of health claims related to Saccharomyces cerevisiae var. boulardii CNCM I‐1079 and defence against pathogenic gastro‐intestinal microorganisms (ID 913, further assessment) pursuant to Article 13(1) of Regu... |
| Q38077632 | Sources, isolation, characterisation and evaluation of probiotics |
| Q43096285 | State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008. |
| Q37976160 | Synbiotics and probiotics in the critically ill after the PROPATRIA trial |
| Q24621081 | Systematic review and meta-analysis of Saccharomyces boulardii in adult patients |
| Q35771988 | Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. |
| Q34487166 | Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea |
| Q37587557 | Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice -- an evidence-based international guide. |
| Q26769725 | THE INTESTINAL MICROBIOTA AND THE ROLE OF PROBIOTICS IN IRRITABLE BOWEL SYNDROME: a review |
| Q57871563 | Taming wildlife disease: bridging the gap between science and management |
| Q42726147 | Targeting intestinal microflora in inflammatory bowel disease |
| Q58643613 | The Challenge of Maintaining a Healthy Microbiome during Long-Duration Space Missions |
| Q38239432 | The Comparison of Food and Supplement as Probiotic Delivery Vehicles |
| Q35144567 | The Enteric Two-Step: nutritional strategies of bacterial pathogens within the gut |
| Q42020494 | The P2Y6 receptor mediates Clostridium difficile toxin-induced CXCL8/IL-8 production and intestinal epithelial barrier dysfunction |
| Q63246529 | The Quest for Novel Antimicrobial Compounds: Emerging Trends in Research, Development, and Technologies |
| Q38055820 | The Role of Probiotics in the Prevention and Treatment of Antibiotic-Associated Diarrhea and Clostridium Difficile Colitis |
| Q28075770 | The Significance of the Enteric Microbiome on the Development of Childhood Disease: A Review of Prebiotic and Probiotic Therapies in Disorders of Childhood |
| Q36889259 | The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge |
| Q43312697 | The effect of a multispecies probiotic on the composition of the faecal microbiota and bowel habits in chronic obstructive pulmonary disease patients treated with antibiotics |
| Q43352809 | The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin |
| Q30874949 | The effect of the macrolide antibiotic tylosin on microbial diversity in the canine small intestine as demonstrated by massive parallel 16S rRNA gene sequencing |
| Q58327081 | The effects of consuming probiotic-fermented milk on the immune system: A review of scientific evidence |
| Q41385038 | The impact of orally administered phages on host immune response and surrounding microbial communities |
| Q37111226 | The management of Clostridium difficile infection: antibiotics, probiotics and other strategies |
| Q37424366 | The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea |
| Q91806621 | The pros, cons, and many unknowns of probiotics |
| Q34989914 | The role of lactobacillus probiotics in the treatment or prevention of urogenital infections--a systematic review |
| Q38174603 | The role of probiotics and prebiotics in inducing gut immunity. |
| Q57245618 | The use of probiotics in gastrointestinal diseases |
| Q37401586 | The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium difficile-associated diarrhea |
| Q28573133 | Transduction pathways regulating the trophic effects of Saccharomyces boulardii in rat intestinal mucosa |
| Q37892763 | Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. |
| Q83162042 | Treating childhood allergy with gut microbes: facts or fiction? |
| Q38442257 | Treatment of Clostridium difficile infection in pediatric patients |
| Q38079363 | Treatment of chronic diarrhoea |
| Q42230752 | Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii |
| Q64098489 | Treatment with and Nissle is safe and associated with reduced nosocomial transmission of B vancomycin-resistant on an early rehabilitation ward in Germany: a retrospective analysis |
| Q37182888 | Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives |
| Q92992517 | Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast Saccharomyces cerevisiae var. boulardii |
| Q39233059 | Unraveling the Differences between Gram-Positive and Gram-Negative Probiotics in Modulating Protective Immunity to Enteric Infections. |
| Q37050248 | Update on the changing epidemiology of Clostridium difficile-associated disease |
| Q37877391 | Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection |
| Q29394639 | Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial |
| Q37823328 | Use of probiotics in gastrointestinal disorders: what to recommend? |
| Q34144918 | Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review |
| Q26795429 | WSES guidelines for management of Clostridium difficile infection in surgical patients |
Search more.